Volume 24, Issue 164 (2-2018)                   RJMS 2018, 24(164): 21-34 | Back to browse issues page

XML Persian Abstract Print


Islamic Azad University, Najafabad, Isfahan, Iran , hadiyanmaryam@gmail.com
Abstract:   (6099 Views)
Background: The purpose of the present study was to investigate the effectiveness of acceptance & commitment therapy on separation anxiety disorder in children with type 1 diabetes.
Methods: A semi-experimental method with pretest-posttest and follow up, including control group were used. Statistical population included all children with type 1 diabetes that had referred to diabetes treatment centers in Najaf Abad town in 2014-2015. The instrument used in this study was Screen for Child Anxiety Related Disorders (SCARED). All students filled the questionnaires and among them, 24 students whose scores were higher were selected and randomly assigned into two experimental and control groups (n1=n2=12). Students in the experimental group were offered eight sessions of acceptance & commitment therapy and control subjects received no therapy in this while then after six month follow up was executed. Data were analyzed by Analyze of covariance method (ANCOVA).
Results: Findings showed that mean score of separation anxiety in children in post-test and follow-up in comparison with pretest had a significant decline. With controlling pretest scores, Acceptance & Commitment therapy caused a significant decrease in separation anxiety scores of children suffering with diabetes type 1, in post-test (F=92.78, p≤0.0001) and also caused significant decrease in anxiety of children, at the end of 6 month follow-up period (F=43.77, p≤0.0001).
Conclusion: After all, results of the current study showed that acceptance & commitment therapy can be used for reducing separation anxiety disorder.
Full-Text [PDF 412 kb]   (7649 Downloads)    
Type of Study: Research | Subject: Clinical Psychiatry

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.